Grant Search

Cancer Type

Keyword Search  

Categories

Grant Amount
>=

<=





Results: 65

Protein degradation as a strategy to target mutant WIP1 in ...

Close to 20% of Diffuse Intrinsic Pontine Gliomas (DIPGs) harbor a mutation in a gene called PPM1D that leads to expression of a truncated form of a protein called WIP1. We have found PPM1D-mutant DIPG cells to require expression of WIP1, rendering it an attractive therapeutic target for these ...

Testing cytotoxic effects and deciphering signalling pathways engaged by a ...

Glioblastoma (GBM) is the most common malignant brain tumor, being highly invasive and not responsive to standard treatment (surgery, radiotherapy, and chemotherapy). Moreover, a major determinant of the high lethality of GBM is the presence of self-renewing, tumorigenic glioblastoma stem-like cells (GSCs) that threateningly support the development and the progressive ...

Photodynamic therapy of diffuse intrinsic pontine glioma in combination with ...

Diffuse intrinsic pontine glioma (DIPG) is a lethal childhood brain tumor and a leading cause of pediatric brain tumor-related mortality. Even with treatment, the median survival of patients with DIPG is 9–11 months. Despite a number of clinical trials, no treatments have proven more effective than radiation therapy (RT) for ...

Unlocking the translational potential of the DIPG epigenome for a ...

Diffuse intrinsic pontine glioma (DIPG) is a malignant pediatric brain tumor with a very poor outlook, with an expected survival of one year. Lack of access to biological tissue sample continues to be the largest barrier to advancing treatment. In 2016, the World Health Organization (WHO) reclassified DIPG tumors as diffuse ...

Targeting Group 4 medulloblastoma via Musashi1-cell cycle inhibition

Despite recent progress in medulloblastoma treatment, two main problems remain. High risk groups 3 and 4 medulloblastoma patients still show a high rate of mortality. Even in the case of success, patients are frequently left with devastating neurocognitive and other sequelae. Therefore, more effective and less aggressive therapies are still in demand. ...